# OnCo record orm-5029 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/orm-5029/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "orm-5029" ;
  schema:name "ORM-5029"@en ;
  schema:description "ORM-5029 is a degrader-antibody conjugate from Orum Therapeutics that reached phase 1 for HER2-expressing advanced solid tumours, including HER2-positive breast cancer; development has stopped."@en ;
  schema:url <https://onco.cc/drugs/orm-5029/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://www.1stoncology.com/blog/?p=102707>, <https://clinicaltrials.gov/study/NCT05511844>, <https://clinicaltrials.gov/search?intr=ORM-5029> ;
  onco:status "phase-1" ;
  onco:tag "pipeline", "ctgov-ingest", "discontinued" ;
  onco:modality "Degrader-antibody conjugate" ;
  onco:cancers <https://onco.cc/cancers/breast-her2-positive/> ;
  onco:targets <https://onco.cc/targets/her2/> ;
  onco:companies <https://onco.cc/companies/orum-therapeutics/> ;
  onco:trials <https://onco.cc/trials/nct05511844/> .